News

Lumos Diagnostics Receives Authorization for CoviDx™ SARS-CoV-2 Rapid Antigen Test in Canada

November 3, 2021

MELBOURNE, VIC. (03 November 2021): Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that Health Canada has granted Interim Order authorization for the Lumos CoviDx™ SARS-CoV-2 Rapid Antigen Test. The CoviDx test gives qualified … Continued

READ MORE
October 24, 2021

Box Hill Hospital Emergency Department Initiates Trial Using FebriDx®

MELBOURNE, VIC. (24 October 2021) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Emergency Department at Box Hill Hospital in Melbourne, Australia, has initiated a 300-subject investigator-led trial using Lumos’ FebriDx® … Continued

READ MORE
October 6, 2021

Economic Evaluation of Lumos Diagnostics’ FebriDx® Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually

SARASOTA, Fla. (October 6, 2021) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Journal of Health Economics and Outcomes Research (JHEOR) has published an economic study that concludes using the FebriDx® … Continued

READ MORE
September 13, 2021

Dr. Jerome Adams, Former U.S. Surgeon General, Joins Lumos Diagnostics as a Strategic Healthcare Adviser

Immediate former U.S. Surgeon General, Jerome Adams, MD, MPH, will join Lumos as a Strategic Healthcare Adviser and will be appointed to the Company’s Medical Advisory Board.

READ MORE
August 30, 2021

Lumos Diagnostics FY21 Full Year Results

Lumos announced its FY21 full year results including Appendix 4E and Annual Report to Shareholders for the fiscal year ending on 30 June 2021.

READ MORE
July 8, 2021

Lumos Diagnostics Raises $63M AUD in ASX IPO

Lumos has been admitted to the Australian Securities Exchange (ASX) with trading commencing on July 5, 2021 after raising $63 million AUD in an Initial Public Offering (IPO).

READ MORE
May 5, 2021

Lumos Diagnostics Appoints Three Industry Leaders as Independent Directors

Lumos Diagnostics announced today the expansion of its board with the appointment of three new independent directors to support the continued growth of the company’s rapid point-of-care diagnostic products and services business.

READ MORE

Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.